Uniqure NV (QURE)

Currency in USD
16.978
-0.112(-0.66%)
Real-time Data·
QURE is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
16.76017.545
52 wk Range
8.73071.500
Key Statistics
Prev. Close
17.09
Open
17.3
Day's Range
16.76-17.545
52 wk Range
8.73-71.5
Volume
397.33K
Average Vol. (3m)
3.26M
1-Year Change
76.0622%
Book Value / Share
3.19
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
QURE Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
38.614
Upside
+127.44%
Members' Sentiments
Bearish
Bullish
ProTips
4 analysts have revised their earnings downwards for the upcoming period

Uniqure NV News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Compare QURE to Peers and Sector

Metrics to compare
QURE
Peers
Sector
Relationship
P/E Ratio
−5.3x−2.1x−0.5x
PEG Ratio
−0.180.120.00
Price / Book
5.3x3.5x2.6x
Price / LTM Sales
66.0x11.3x3.2x
Upside (Analyst Target)
106.4%131.1%47.6%
Fair Value Upside
Unlock6.0%6.1%Unlock

Analyst Ratings

9 Buy
4 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 38.614
(+127.44% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Barclays
Hold25.00+47.58%31.00MaintainMar 23, 2026
Mizuho
Buy35.00+106.61%12.00UpgradeMar 10, 2026
Chardan
Buy31.00+83.00%16.00MaintainMar 09, 2026
Wells Fargo
Buy60.00+254.19%15.00UpgradeMar 09, 2026
RBC Capital
Buy35.00+106.61%11.00UpgradeMar 09, 2026

Earnings

Latest Release
Mar 02, 2026
EPS / Forecast
-0.57 / -0.92
Revenue / Forecast
5.57M / 5.29M
EPS Revisions
Last 90 days

QURE Income Statement

People Also Watch

141.568
AAOI
-3.29%
33.690
PL
-0.71%
465.56
CIEN
-0.35%
832.01
LITE
-2.44%
161.99
CRDO
+1.55%

FAQ

What Is the Uniqure NV (QURE) Stock Price Today?

The Uniqure NV stock price today is 16.978 USD.

What Stock Exchange Does Uniqure NV Trade On?

Uniqure NV is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Uniqure NV?

The stock symbol for Uniqure NV is "QURE."

What Is the Uniqure NV Market Cap?

As of today, Uniqure NV market cap is 1.060B USD.

What Is Uniqure NV's Earnings Per Share (TTM)?

The Uniqure NV EPS (TTM) is -3.460.

When Is the Next Uniqure NV Earnings Date?

Uniqure NV will release its next earnings report on May 12, 2026.

From a Technical Analysis Perspective, Is QURE a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Uniqure NV Stock Split?

Uniqure NV has split 0 times.

How Many Employees Does Uniqure NV Have?

Uniqure NV has 221 employees.

What is the current trading status of Uniqure NV (QURE)?

As of Apr 15, 2026, Uniqure NV (QURE) is trading at a price of 16.978 USD, with a previous close of 17.090 USD. The stock has fluctuated within a day range of 16.760 USD to 17.545 USD, while its 52-week range spans from 8.730 USD to 71.500 USD.

What Is Uniqure NV (QURE) Price Target According to Analysts?

The average 12-month price target for Uniqure NV is 38.614 USD, with a high estimate of 96.65841 USD and a low estimate of 9.08940788 USD. 9 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +127.44% Upside potential.

What Is the QURE Premarket Price?

QURE's last pre-market stock price is 17.020 USD. The pre-market share volume is 363.000, and the stock has decreased by -0.070, or -0.410%.

What Is the QURE After Hours Price?

QURE's last after hours stock price is 17.060 USD, the stock has decreased by -0.030, or -0.180%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.